News

The pharma and biotech exec will begin his role on Aug. 1.

One billion DSCSA transaction histories were reportedly processed on the company network.

William Fletcher brings his serialization and traceability knowledge to the healthcare solutions company.

CDMO’s Turku addition will span over 69,000 square feet and support the production of ATMPs.

Pandemic preparedness and curbing PBMs among the pending legislation that will have to wait until after summer recess.

Drug safety database can now be used by life sciences organizations that are looking to develop, manufacture, and market regulated products in the country.

The logistics provider is now a member of an industry group of experts in Italy.

Purchase helps expands business’ label and packing services.

Product reportedly offers enhanced pharma supply chain visibility and risk analysis.

Collaboration aims to help pharmaceuticals drive efficiencies and business value.

With FDA’s compliance deadline only three months away, the tech-supply chain partnership is expected to help manufacturers and wholesalers meet the Nov. 27 deadline.

Sterile injectable plant—struck by tornado—is currently being assessed.

With goal of improving patients’ overall care, Pittsburgh-based pharmacy is aiming to be licensed in all 50 states.

Solution includes assistance with submitting regulatory submissions.

The agency proposes significant revisions to oversight programs for drugs and medical products.

Company anticipates launch of a standalone organization.

The 19,500 square-foot warehouse will support API manufacturing activities, all the way through commercialization.

Experienced exec joins the agency with over three decades of driving brand growth.

Executive joins PTC with finance strategy experience, particularly as it pertains to biopharma.

Agency claims union would threaten a monopoly on programmatic advertising space.

The debut will be the CDMO’s first fully automated sterile injectable manufacturing line at the Wuxi, China site.

Report reiterates CDMO’s commitment to net-zero emissions.

Annual industry seminar will help address compliance obstacles, as the DSCSA deadline approaches.

Demand comes among antitrust agency’s recent denial of Amgen’s Horizon buyout.

Goal of the deal is to boost the production of oral dosage forms.

The 50,000 square-foot facility will feature 10 new manufacturing sites with commercial capabilities.

Recent data and commentary offer insights into how biologics vs. small molecule patent protections under the Inflation Reduction Act pricing scenarios is impacting investing in the biotech sector.

Ruling validates antitrust theory, pushes antitrust arbitration against Prime Therapeutics forward.